PhRMA Says FDA Coupon Study Oversteps Price Regulation Boundaries
Executive Summary
The Pharmaceutical Research and Manufacturers of America is concerned that FDA's plans to study the impact of coupons embedded in print ads on consumer perceptions is beyond the scope of the agency's authority
You may also be interested in...
FDA’s DTC Coupon Study Triggers First Amendment Objections From PhRMA
FDA’s third attempt at studying the effects of coupons in direct-to-consumer print advertising triggers First Amendment concerns and raises the specter of regulatory restrictions based upon “potential deception,” according to the Pharmaceutical Research and Manufacturers of America.
FDA’s DTC Coupon Study Triggers First Amendment Objections From PhRMA
FDA’s third attempt at studying the effects of coupons in direct-to-consumer print advertising triggers First Amendment concerns and raises the specter of regulatory restrictions based upon “potential deception,” according to the Pharmaceutical Research and Manufacturers of America.
FDA To Study Impact of Coupons In Print DTC Ads
Study signals increasing agency efforts to monitor promotional activities for firms.